title: Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy.
abstract: OBJECTIVE
  Patients with multiple myeloma have an increased incidence of venous thromboembolism. The risk for venous thromboembolism further increases when these patients are placed on immunomodulatory drug therapy. This study aims to determine the incidence of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory drug therapy in the ambulatory setting at UC Health and to investigate adherence with guidelines developed by The National Comprehensive Cancer Network for venous thromboembolism prevention in this patient population.
  
  
  METHODS
  A retrospective chart review of patients with multiple myeloma initiated on immunomodulatory drug therapy between January 2000 and January 2014 was conducted.
  
  
  RESULTS
  Sixty-two cases met inclusion criteria and were included for analysis. The National Comprehensive Cancer Network guidelines were followed in 33.9% of cases. The rate of venous thromboembolism was 4.8% in guideline adherent cases and 12.2% in guideline nonadherent cases (p = 0.65). The overall incidence of venous thromboembolism was 9.7%. No patients on a low-molecular-weight-heparin agent or warfarin developed a venous thromboembolism, 7.9% patients on aspirin therapy developed a venous thromboembolism, and 23.1% patients on no pharmacologic thromboprophylaxis developed a venous thromboembolism (p = 0.26).
  
  
  CONCLUSIONS
  Ambulatory patients with multiple myeloma who are considered for immunomodulatory drug therapy should be placed on pharmacologic thromboprophylaxis based on individual venous thromboembolism and bleeding risk factors. This study identified the need for increased adherence to national guidelines for venous thromboembolism prevention in patients with multiple myeloma receiving immunomodulatory drug therapy so as to increase the quality of care provided at UC Health.
authors: Department of Pharmacy Services, UC Health-University of Cincinnati Medical Center, Cincinnati, USA ruthdede@outlook.com.
authors: Ruth J
authors: RJ
authors: Dede
authors: James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, USA.
authors: Jane M
authors: JM
authors: Pruemer
mesh_terms: D000368:Aged; D000553:Ambulatory Care / Q000379:methods*; D000925:Anticoagulants / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D056747:Immunomodulation; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D065129:Pre-Exposure Prophylaxis / Q000379:methods*; D012189:Retrospective Studies; D054556:Venous Thromboembolism / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants
keywords: Multiple myeloma; immunomodulatory drug; prophylaxis; venous thromboembolism